SCHEMBL5651833

SCHEMBL5651833

CCc1cc(-c2oncc2-c2ccc(OC)cc2)c(OCc2ccccc2)cc1OC

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.67
KMT2A Q03164 1/20 0.67
SYK P43405 4/20 0.43
MAPT P10636 2/20 0.43
NPSR1 Q6W5P4 2/20 0.43
MAPK1 P28482 1/20 0.43
NOD2 Q9HC29 1/20 0.43
CTSL P07711 1/20 0.42
CTSB P07858 1/20 0.42
ABCB1 P08183 1/20 0.41
C5AR1 P21730 1/20 0.41
CSNK2A2 P19784 1/20 0.41
CSNK2A1 P68400 1/20 0.41
PPARG P37231 1/20 0.40
AURKB Q96GD4 1/20 0.40
INCENP Q9NQS7 1/20 0.40
GSTP1 P09211 1/20 0.40
GSK3B P49841 1/20 0.40
CDK5 Q00535 1/20 0.40
CDK5R1 Q15078 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5651574 0.87 MEN1 (0.82) MEN1KMT2AMAPTNPSR1MAPK1
SCHEMBL14474303 0.85 KMT2A (0.72) MEN1KMT2ASYKMAPTNPSR1
SCHEMBL30078294 0.80 KMT2A (1.00) MEN1KMT2AMAPTNPSR1MAPK1
SCHEMBL1167690 0.80 KMT2A (1.00) MEN1KMT2AMAPTNPSR1MAPK1
SCHEMBL5651180 0.77 MEN1 (0.65) MEN1KMT2AMAPTNPSR1MAPK1
SCHEMBL1168174 0.75 MEN1 (0.61) MEN1KMT2AGSK3B
SCHEMBL5653865 0.74 MEN1 (0.84) MEN1KMT2AMAPTNPSR1MAPK1
SCHEMBL2940825 0.74 SMN1; SMN2 (0.48) SYKMAPTNPSR1MAPK1NOD2
SCHEMBL1167880 0.73 KMT2A (0.66) MEN1KMT2AMAPT
SCHEMBL1167168 0.72 MEN1 (0.76) MEN1KMT2AMAPTNPSR1MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7250432-B2 Pharmaceutical compositions of diaryl-isoxazole derivatives for the prevention and treatment of cancers KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY (KR) 2007-07-31 US claimed
US-20050131036-A1 Pharmaceutical compositions of diaryl-isoxazole derivatives for the prevention and treatment of cancers KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY (KR) 2005-06-16 US claimed
US-7250432-B2 Pharmaceutical compositions of diaryl-isoxazole derivatives for the prevention and treatment of cancers KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY (KR) 2007-07-31 US disclosed
US-7250432-B2 Pharmaceutical compositions of diaryl-isoxazole derivatives for the prevention and treatment of cancers KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY (KR) 2007-07-31 US disclosed
US-20050131036-A1 Pharmaceutical compositions of diaryl-isoxazole derivatives for the prevention and treatment of cancers KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY (KR) 2005-06-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050131036-A1 Pharmaceutical compositions of diaryl-isoxazole derivatives for the prevention and treatment of cancers UACA, SQLE, ALDH1A2 MEN1 3914/4885KMT2A 4307/4885SYK 765/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.